
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+9
We are a biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. We are utilizing our proprietary FUSIONTM System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Our lead...
Biotech,oncology,patient friendly therapies ,targeted medicine ,cancer treatment,acute myeloid leukemia,mll fusion,diabetes mellitus,liquid tumors,solid tumors,innovative medicine ,novel mechanism of action,menin,and irreversible inhibitors
Biomea fusion operates in the Biotechnology research industry.
Biomea fusion's revenue is 11m - 100m
Biomea fusion has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.